Napaporn Apiratmateekul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Napaporn Apiratmateekul has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Wanvisa Treebuphachatsakul
Reference Materials and Innovation Research Unit for Medical Laboratory, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand
5 shared publications - Gerald Joseph Kost
Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, CA 95616, USA
3 shared publications - Nam Khoa Tran
Computational Pathology and AI Center of Excellence (CPACE), School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
3 shared publications - Supaporn Suparak
Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand
2 shared publications - Butsabawan Chaireunsung
We Med Lab Proficiency Testing Center, WE Med Lab Center Co., Ltd., Phitsanulok 65000, Thailand
1 shared publication - Jintana Nammoonnoy
National Institute of Metrology (Thailand), Prathum Thani 12120, Thailand
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (19) , 3252
Performance Assessment of Centrifugation-Based Hematocrit Testing in Primary Care Units: Evidence from Seventy-Two Proficiency Testing Datasets over Eight Years
Background: Centrifugation-based hematocrit (Hct) testing remains widely used in decentralized primary care settings where access to automated hematology analyzers may be limited. Appropriate proficiency testing (PT) performance assessment therefore requires consideration of the analytical variability associated with this measurement method. This study evaluated longitudinal PT data to characterize method-specific variability and compare alternative approaches to RSD estimation for centrifugation-based Hct testing. Methods: Seventy-two datasets from 32 PT rounds conducted during 2017–2024 were analyzed, with 12 to 310 participants per dataset. PT materials were assessed for homogeneity and stability in accordance with ISO 13528. The relative standard deviation (RSD) was estimated using two approaches: Method A, based on all statistically processed valid results to reflect total interlaboratory variability, and Method B, based on the satisfactory-performance subset (∣z∣ ≤ 2), within which robust statistics were recalculated. Temporal trends were evaluated by linear regression using dataset-specific RSD values. Sensitivity analysis evaluated Method B using alternative z-score inclusion thresholds of ∣z∣ ≤ 1.5, 2.0, 2.5, and 3.0. Performance classifications in 2024 were compared descriptively. Results: All PT materials met predefined homogeneity and stability criteria. The final cumulative pooled relative standard deviation (RSDpooled) was 10.81% for Method A and 4.86% for Method B. was 10.81% for Method A and 4.86% for Method B. Method A showed an increasing temporal trend, whereas Method B showed minimal temporal change; however, participant numbers increased substantially over the study period and may have contributed to the Method A trend. Sensitivity analysis showed that Method B was threshold-dependent, with final RSDpooled values of 3.90%, 4.86%, 5.59%, and 6.28% at ∣z∣ ≤ 1.5, 2.0, 2.5, and 3.0, respectively. In the 2024 datasets, satisfactory rates ranged from 75.68–99.12% for Method A and 43.15–95.61% for Method B. Conclusions: Methods A and B provide complementary information whereas Method B characterizes dispersion among participants meeting a predefined satisfactory-performance criterion. The Method B RSDpooled of 4.86% is specific to inclusion criterion and should not be interpreted as a threshold-independent estimate of analytical imprecision. Further studies using prospectively defined statistical methods and appropriately structured participant-level data are needed to determine its potential utility for PT/EQA performance assessment.
- 8 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (19) , 3252
Open AccessPerformance Assessment of Centrifugation-Based Hematocrit Testing in Primary Care Units: Evidence from Seventy-Two Proficiency Testing Datasets over Eight Years
Background: Centrifugation-based hematocrit (Hct) testing remains widely used in decentralized primary care settings where access to automated hematology analyzers may be limited. Appropriate proficiency testing (PT) performance assessment therefore requires consideration of the analytical variability associated with this measurement method. This study evaluated longitudinal PT data to characterize method-specific variability and compare alternative approaches to RSD estimation for centrifugation-based Hct testing. Methods: Seventy-two datasets from 32 PT rounds conducted during 2017–2024 were analyzed, with 12 to 310 participants per dataset. PT materials were assessed for homogeneity and stability in accordance with ISO 13528. The relative standard deviation (RSD) was estimated using two approaches: Method A, based on all statistically processed valid results to reflect total interlaboratory variability, and Method B, based on the satisfactory-performance subset (∣z∣ ≤ 2), within which robust statistics were recalculated. Temporal trends were evaluated by linear regression using dataset-specific RSD values. Sensitivity analysis evaluated Method B using alternative z-score inclusion thresholds of ∣z∣ ≤ 1.5, 2.0, 2.5, and 3.0. Performance classifications in 2024 were compared descriptively. Results: All PT materials met predefined homogeneity and stability criteria. The final cumulative pooled relative standard deviation (RSDpooled) was 10.81% for Method A and 4.86% for Method B. was 10.81% for Method A and 4.86% for Method B. Method A showed an increasing temporal trend, whereas Method B showed minimal temporal change; however, participant numbers increased substantially over the study period and may have contributed to the Method A trend. Sensitivity analysis showed that Method B was threshold-dependent, with final RSDpooled values of 3.90%, 4.86%, 5.59%, and 6.28% at ∣z∣ ≤ 1.5, 2.0, 2.5, and 3.0, respectively. In the 2024 datasets, satisfactory rates ranged from 75.68–99.12% for Method A and 43.15–95.61% for Method B. Conclusions: Methods A and B provide complementary information whereas Method B characterizes dispersion among participants meeting a predefined satisfactory-performance criterion. The Method B RSDpooled of 4.86% is specific to inclusion criterion and should not be interpreted as a threshold-independent estimate of analytical imprecision. Further studies using prospectively defined statistical methods and appropriately structured participant-level data are needed to determine its potential utility for PT/EQA performance assessment.
- Open Access
- 12 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1813
Development and Characterization of Dual-Platform Lyophilized Plasma-Based Quality Control Materials for Hepatitis C Virus Antibody Testing
Background/Objectives: Reliable quality control (QC) materials are essential for maintaining the analytical performance of hepatitis C virus (HCV) screening assays. Rapid diagnostic tests (RDTs) are widely used for point-of-care HCV screening; however, standardized plasma-based internal quality control (IQC) materials compatible with both rapid tests and automated immunoassays remain limited. This study aimed to develop and evaluate plasma-based QC materials applicable to multiple anti-HCV RDTs and automated immunoassays. Methods: QC materials were prepared from pooled HCV-positive plasma at strong-positive, weak-positive, and negative levels in liquid and lyophilized formats. Lyophilized preparations were produced with and without trehalose, while liquid samples were prepared with and without a stabilizer. Performance was evaluated using five anti-HCV RDT kits and the Elecsys Anti-HCV II automated immunoassay platform. Stability was assessed under accelerated temperature conditions (45 °C for 28 days) and long-term storage (2–8 °C and 20–30 °C for six months). Signal trends were analyzed using linear regression (p > 0.05), and homogeneity was evaluated using one-way analysis of variance and Cochran’s C test. Results: All QC formulations demonstrated consistent qualitative reactivity across the evaluated RDT kits and stable responses on the automated immunoassay platform. Lyophilized plasma containing trehalose maintained stable cut-off index (COI) values during accelerated and long-term storage, with no significant time-dependent trends (p > 0.05). Conclusions: Trehalose-stabilized lyophilized materials demonstrated enhanced stability and acceptable homogeneity, supporting practical applicability under the tested storage conditions across the evaluated rapid tests, and within the evaluated moderate-to-high positive analytical ranges on the automated anti-HCV immunoassay platform.
- 12 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1813
Open AccessDevelopment and Characterization of Dual-Platform Lyophilized Plasma-Based Quality Control Materials for Hepatitis C Virus Antibody Testing
Background/Objectives: Reliable quality control (QC) materials are essential for maintaining the analytical performance of hepatitis C virus (HCV) screening assays. Rapid diagnostic tests (RDTs) are widely used for point-of-care HCV screening; however, standardized plasma-based internal quality control (IQC) materials compatible with both rapid tests and automated immunoassays remain limited. This study aimed to develop and evaluate plasma-based QC materials applicable to multiple anti-HCV RDTs and automated immunoassays. Methods: QC materials were prepared from pooled HCV-positive plasma at strong-positive, weak-positive, and negative levels in liquid and lyophilized formats. Lyophilized preparations were produced with and without trehalose, while liquid samples were prepared with and without a stabilizer. Performance was evaluated using five anti-HCV RDT kits and the Elecsys Anti-HCV II automated immunoassay platform. Stability was assessed under accelerated temperature conditions (45 °C for 28 days) and long-term storage (2–8 °C and 20–30 °C for six months). Signal trends were analyzed using linear regression (p > 0.05), and homogeneity was evaluated using one-way analysis of variance and Cochran’s C test. Results: All QC formulations demonstrated consistent qualitative reactivity across the evaluated RDT kits and stable responses on the automated immunoassay platform. Lyophilized plasma containing trehalose maintained stable cut-off index (COI) values during accelerated and long-term storage, with no significant time-dependent trends (p > 0.05). Conclusions: Trehalose-stabilized lyophilized materials demonstrated enhanced stability and acceptable homogeneity, supporting practical applicability under the tested storage conditions across the evaluated rapid tests, and within the evaluated moderate-to-high positive analytical ranges on the automated anti-HCV immunoassay platform.
- Open Access
- 19 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (4) , 608
Development and Evaluation of a Lyophilized Plasma-Based Internal Quality Control for Human Immunodeficiency Virus Rapid Diagnostic Tests
Background/Objectives: Rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV) are widely used, but most kits lack standardized internal quality control (IQC) materials. In this study, we aimed to develop and evaluate a plasma-based IQC compatible with five HIV RDT brands and with proven long-term stability. Methods: Control samples at three reactivity levels were tested with five HIV RDT kits in lyophilized and liquid forms. Lyophilized samples were produced with and without trehalose, whereas liquid samples were prepared with and without StabilZyme™ SELECT Stabilizer (Stabilizer). Accelerated stability testing was performed at 37 °C and 45 °C for 28 days, and the most stable formulation was selected for long-term storage at 4 ± 2 °C and 25 ± 5 °C. Stability was assessed based on test-line visibility and signal intensity. Signal-intensity trends were analyzed using simple linear regression with a t-test on the slope; samples were considered stable when no significant trend was detected (p > 0.05). Results: Reactivity measured using the Elecsys HIV combi PT assay yielded cutoff index (COI) values of 772.65 (1:8) for the strong-positive control and 269.95 (1:25) for the weak-positive control. Trehalose-containing lyophilized samples maintained reactivity under accelerated testing at 37 and 45 °C and for 6 months at 4 ± 2 °C and 25 ± 5 °C, with no significant change in signal intensity (p > 0.05). Conclusions: The plasma-based IQC materials were compatible with all five HIV RDTs, and trehalose-stabilized lyophilized plasma showed high stability, supporting transport and storage without strict cold-chain requirements.
- 19 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (4) , 608
Open AccessDevelopment and Evaluation of a Lyophilized Plasma-Based Internal Quality Control for Human Immunodeficiency Virus Rapid Diagnostic Tests
Background/Objectives: Rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV) are widely used, but most kits lack standardized internal quality control (IQC) materials. In this study, we aimed to develop and evaluate a plasma-based IQC compatible with five HIV RDT brands and with proven long-term stability. Methods: Control samples at three reactivity levels were tested with five HIV RDT kits in lyophilized and liquid forms. Lyophilized samples were produced with and without trehalose, whereas liquid samples were prepared with and without StabilZyme™ SELECT Stabilizer (Stabilizer). Accelerated stability testing was performed at 37 °C and 45 °C for 28 days, and the most stable formulation was selected for long-term storage at 4 ± 2 °C and 25 ± 5 °C. Stability was assessed based on test-line visibility and signal intensity. Signal-intensity trends were analyzed using simple linear regression with a t-test on the slope; samples were considered stable when no significant trend was detected (p > 0.05). Results: Reactivity measured using the Elecsys HIV combi PT assay yielded cutoff index (COI) values of 772.65 (1:8) for the strong-positive control and 269.95 (1:25) for the weak-positive control. Trehalose-containing lyophilized samples maintained reactivity under accelerated testing at 37 and 45 °C and for 6 months at 4 ± 2 °C and 25 ± 5 °C, with no significant change in signal intensity (p > 0.05). Conclusions: The plasma-based IQC materials were compatible with all five HIV RDTs, and trehalose-stabilized lyophilized plasma showed high stability, supporting transport and storage without strict cold-chain requirements.
- Open Access
- 20 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (18) , 2398
Novel Blood Collection Tubes Improve Sample Preservation in a Multicenter Study in Thailand
Background: Blood collection tubes (BCTs) are critical in vitro diagnostic devices used in clinical laboratory testing. Innomed tubes are novel BCTs coated with heparin and anti-glycolytic agents (Innomed 1) and clot activators combined with anti-glycolytic agents (Innomed 2). This study, we focus on the verification and multicenter validation of Innomed tubes, aiming to assess their performance in glucose stability, hemolysis resistance, and biochemical interferences relevant to diabetes and non-communicable disease (NCD) monitoring. Methods: Two types of Innomed tubes were evaluated. The verification process, conducted in a reference laboratory, assessed biochemical interferences, glucose stability, and the potential for hemolysis due to centrifugation and blood collection techniques. The multicenter validation of biochemical interferences was carried out across five hospital laboratories. Subsequently, samples were centrifuged at 3500 rpm for 5–10 min and analyzed immediately after separation, not exceeding 2 h from collection. Results: Glucose levels in Innomed 1 and 2 remained stable within 8% of up to 8 h post-collection. No hemolysis was observed under varying centrifugation times (at 3500 rpm) and blood collection techniques, as confirmed through visual inspection and lactate dehydrogenase level determinations. Innomed tubes were suitable BCTs for glucose, HbA1c, thyroid stimulating hormone, free triiodothyronine, free thyroxin, triiodothyronine, carcinoembryonic antigen, and prostate-specific antigen, as well as for 19 routine biochemical assays. Conclusions: Innomed 1 and 2 BCTs maintain blood glucose stability for 8 h, ensuring accurate biochemical, HbA1c, thyroid, and tumor marker testing. Their hemolysis resistance supports diabetes screening and Non-Communicable Diseases (NCD) monitoring. thereby emphasizing their clinical relevance in chronic disease management.
- 20 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (18) , 2398
Open AccessNovel Blood Collection Tubes Improve Sample Preservation in a Multicenter Study in Thailand
Background: Blood collection tubes (BCTs) are critical in vitro diagnostic devices used in clinical laboratory testing. Innomed tubes are novel BCTs coated with heparin and anti-glycolytic agents (Innomed 1) and clot activators combined with anti-glycolytic agents (Innomed 2). This study, we focus on the verification and multicenter validation of Innomed tubes, aiming to assess their performance in glucose stability, hemolysis resistance, and biochemical interferences relevant to diabetes and non-communicable disease (NCD) monitoring. Methods: Two types of Innomed tubes were evaluated. The verification process, conducted in a reference laboratory, assessed biochemical interferences, glucose stability, and the potential for hemolysis due to centrifugation and blood collection techniques. The multicenter validation of biochemical interferences was carried out across five hospital laboratories. Subsequently, samples were centrifuged at 3500 rpm for 5–10 min and analyzed immediately after separation, not exceeding 2 h from collection. Results: Glucose levels in Innomed 1 and 2 remained stable within 8% of up to 8 h post-collection. No hemolysis was observed under varying centrifugation times (at 3500 rpm) and blood collection techniques, as confirmed through visual inspection and lactate dehydrogenase level determinations. Innomed tubes were suitable BCTs for glucose, HbA1c, thyroid stimulating hormone, free triiodothyronine, free thyroxin, triiodothyronine, carcinoembryonic antigen, and prostate-specific antigen, as well as for 19 routine biochemical assays. Conclusions: Innomed 1 and 2 BCTs maintain blood glucose stability for 8 h, ensuring accurate biochemical, HbA1c, thyroid, and tumor marker testing. Their hemolysis resistance supports diabetes screening and Non-Communicable Diseases (NCD) monitoring. thereby emphasizing their clinical relevance in chronic disease management.
- Open Access
- 11 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (8) , 799
Commutable Blood Materials from the Fixed-Cell Method for Performance Evaluation of Blood Glucose by a Glucose Meter
Glucose meters provide a rapid blood glucose status for evidence-based diagnosis, monitoring, and treatment of diabetes mellitus. We aimed to evaluate the commutability of processed blood materials (PBMs) and their use in the performance evaluation of glucose meters. Two PBMs obtained by the fixed-cell method were analyzed for homogeneity, stability, and commutability. The compatibility of ten pairs between mass spectrometry and each glucose meter was categorized as compatible (mean paired difference ≤ 5%) and incompatible (mean paired difference > 5%). The performance of glucose meter 1 (n = 767) and glucose meter 2 (n = 266) was assessed. The glucose in the PBMs remained homogenized and stable for at least 180 days. Six out of ten pairs had commutable PBMs. Commutability of PBMs was observed in both well-compatible and incompatible glucose results. Target glucose values from mass spectrometry were significantly different (p ≤ 0.05) from consensus values in one group of glucose meters. When commutable PBMs were used, glucose meter 1 showed better performance than glucose meter 2, and the percentage of satisfaction was associated when using target values for glucose from mass spectrometry and consensus values, but the performance of glucose meter 2 was not associated. PBM from a fixed-cell method could be mass produced with acceptable homogeneity and stability. Commutability testing of PBMs is required prior to use in the performance evaluation of glucose meters, as the commutability of glucose in the PBMs obtained by a fixed-cell method was variable and depended on the individual glucose meter.
- 11 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (8) , 799
Open AccessCommutable Blood Materials from the Fixed-Cell Method for Performance Evaluation of Blood Glucose by a Glucose Meter
Glucose meters provide a rapid blood glucose status for evidence-based diagnosis, monitoring, and treatment of diabetes mellitus. We aimed to evaluate the commutability of processed blood materials (PBMs) and their use in the performance evaluation of glucose meters. Two PBMs obtained by the fixed-cell method were analyzed for homogeneity, stability, and commutability. The compatibility of ten pairs between mass spectrometry and each glucose meter was categorized as compatible (mean paired difference ≤ 5%) and incompatible (mean paired difference > 5%). The performance of glucose meter 1 (n = 767) and glucose meter 2 (n = 266) was assessed. The glucose in the PBMs remained homogenized and stable for at least 180 days. Six out of ten pairs had commutable PBMs. Commutability of PBMs was observed in both well-compatible and incompatible glucose results. Target glucose values from mass spectrometry were significantly different (p ≤ 0.05) from consensus values in one group of glucose meters. When commutable PBMs were used, glucose meter 1 showed better performance than glucose meter 2, and the percentage of satisfaction was associated when using target values for glucose from mass spectrometry and consensus values, but the performance of glucose meter 2 was not associated. PBM from a fixed-cell method could be mass produced with acceptable homogeneity and stability. Commutability testing of PBMs is required prior to use in the performance evaluation of glucose meters, as the commutability of glucose in the PBMs obtained by a fixed-cell method was variable and depended on the individual glucose meter.